Skip to main content
GTHRinactive

GENETHERA INC

Biological products·Pre-clinical
Infectious Disease

GTHR evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for GTHR—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

8.0/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

—

Next Catalyst

—

Financial data as of Sep 30, 2022.

Run GENETHERA INC through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available GENETHERA INC facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

No clinical pipeline tracked — this score reflects financial & catalyst signals only.

Cash Runway10.0

Profitable (positive operating cash flow)

Financial Health6.0

OCF $6K · Net income -$126K · Debt/OCF 1.1×

Pipeline MaturityN/A

No tracked pipeline phase

Pipeline BreadthN/A

No tracked pipeline candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Financials

Run my thesis on this company
925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.